Lower Risk of Hepatocellular Carcinoma With TDF vs ETV in Patients With Chronic Hepatitis B From Large Hong Kong Database Analysis

April 10-14, 2019; Vienna, Austria
Reduced risk of HCC with TDF vs ETV maintained in propensity score–weighted analysis of Hong Kong cohort including more than 29,000 patients with CHB.
Format: Microsoft PowerPoint (.ppt)
File Size: 164 KB
Released: April 17, 2019

Acknowledgements

Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Educational grant provided by:
AbbVie
Gilead Sciences

Related Content

Download free expert-authored slides on the clinical interplay of HCV and COVID-19 coinfection and the impact of the COVID-19 pandemic on access to HCV care and treatment

Ricardo Franco, MD Stacey Trooskin, MD, PhD Released: October 7, 2020

Dr. Stefan Zeuzem discusses new viral hepatitis data reported at the 2020 Digital International Liver Congress, in the CCO Infectious Disease podcast

Stefan Zeuzem, MD Released: September 14, 2020

Expert selections of the most important viral hepatitis data from EASL 2020, including HCV elimination and HCV and HBV treatment, provided by CCO

Stefan Zeuzem, MD Released: September 8, 2020

CCO commentary from Anna Christina L. dela Cruz, MD, on the use of quantitative HBsAg and elastography in the management of hepatitis B

Anna Christina L. dela Cruz, MD Released: August 18, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue